Long-term magnesium orotate therapy in patients with mitral valve prolapse
Aim. To assess the effectiveness of long-term treatment with magnesium orotate (Magnerot®), as a pathogenetic therapy, in patients with mitral valve prolapse (MVP). Material and methods. In total, 31 MVP patients, administered Magnerot® (1500 mg/d) in three-month courses, twice a year, were followed...
Saved in:
Main Authors: | A. I. Martynov, A. V. Akatova, O. P. Nikolin |
---|---|
Format: | Article |
Language: | Russian |
Published: |
«SILICEA-POLIGRAF» LLC
2012-06-01
|
Series: | Кардиоваскулярная терапия и профилактика |
Subjects: | |
Online Access: | https://cardiovascular.elpub.ru/jour/article/view/1810 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
EFFECT OF MAGNESIUM OROTATE ON CONNECTIVE TISSUE MATRIX AND CARDIAC INOTROPIC FUNCTION IN PATIENTS WITH MITRAL VALVE PROLAPSE. CLINICAL AND MORPHOLOGICAL STUDY
by: A. G. Avtandilov, et al.
Published: (2015-09-01) -
MAGNESIUM AND MITRAL VALVE PROLAPSE. EFFICACY AND THE POINTS OF APPLICATION
by: A. G. Avtandilov, et al.
Published: (2016-01-01) -
Clinical effectiveness of magnesium orotate in patients with cardiac arrhythmias, arterial hypertension, and mitral valve prolapse
by: E. V. Akatova, et al.
Published: (2009-08-01) -
Extracardiac manifestations of connective tissue dysplasia in mitral valve prolapse
by: A. V. Klemenov
Published: (2004-02-01) -
Connective tissue dysplasia in patients with mitral valve prolapse.
by: M. A. Kuznetsova
Published: (2013-12-01)